1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication
- A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
- 2012
- A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation
- 2010
- Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.
- 2009
- Cyclin B1 Is an Independent Prognostic Proliferation Marker with a High Reproducibility in a Population-Based Lymph Node Negative Breast Cancer Cohort
- 2007
- Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
- 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- 2004
- The Scandinavian Sarcoma Group--background, organization and the SSG Register--the first 25 years
- Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel
- 2003
- Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer